Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The molecular profile of metastatic melanoma in Australia.

Pathology - 1 Feb 2016

Lyle Megan, Haydu Lauren E, Menzies Alexander M, Thompson John F, Saw Robyn P M, Spillane Andrew J, Kefford Richard F, Mann Graham J, Cooper Wendy A, Yu Bing, Scolyer Richard A, O'Toole Sandra A, Long Georgina V

Abstract excerpt

Targeted therapy directed at driver oncogenic mutations offers an effective treatment option for select patients with metastatic melanoma. The aim of this study was to assess the prevalence of clinically significant somatic mutations, specifically BRAF, NRAS and KIT, in a large cohort of Australian patients with metastatic melanoma. We performed a cross-sectional cohort study of consecutive patients with American...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Australia
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-kit

Share to Skin Neoplasms

Source

Identifiers

PMID: 27020391
DOI: 10.1016/j.pathol.2015.12.008

Genes

BRAF
KIT
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The molecular profile of metastatic melanoma in Australia.PMID 27020391Read ↗

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.Semantic proximity Read ↗

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.Semantic proximity Read ↗

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.Semantic proximity Read ↗

Biology and Treatment of BRAF Mutant Metastatic MelanomaSemantic proximity Read ↗

Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.Semantic proximity Read ↗

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.Semantic proximity Read ↗

Mutational Profile of Driver Genes in Brazilian Melanomas.Semantic proximity Read ↗

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Semantic proximity Read ↗

The Current State of Molecular Testing in the BRAF-Mutated Melanoma LandscapeSemantic proximity Read ↗

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.Semantic proximity Read ↗

Concordance of somatic mutational profile in multiple primary melanomas.Semantic proximity Read ↗

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.